Aza-peptide macrocyclic hepatitis C serine protease inhibitors

A compound of Formula I:

• wherein
• A is selected from:
• (a) hydrogen;
• (b) —(C═O)—O—R1, where R1 is selected from:
• 1. hydrogen,
• 2. C1–C6 alkyl,
• 3. C3–C12 cycloalkyl,
• 4. substituted C3–C12 cycloalkyl,
• 5. aryl,
• 6. substituted aryl,
• 7. heteroaryl,
• 8. substituted heteroaryl,
• 9. heterocycloalkyl,
• 10. substituted heterocycloalkyl, or
• 11. —C1–C6 alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;
• (c) —(C═O)—R2, where R2 is selected from:
• 1. —R1, where R1 is as previously defined,
• 2. alkylamino,
• 3. dialkyl amino,
• 4. arylamino, or
• 5. diarylamino;
• (d) —C(═O)—NH—R2, where R2 is as previously defined;
• (e) —C(═S)—NH—R2, where R2 is as previously defined;
• (f) —S(O)2—R2, where R2 is as previously defined;
• B is hydrogen or C1–C6 alkyl;
• G is
• (a) —OH;
• (b) —O—(C1–C12 alkyl);
• (c) —NH—R2, where R2 is as previously defined;
• (d) —NHS(O)2—R1, where R1 as previously defined;
• (e) —(C═O)—R2, where R2 as previously defined;
• (f) —(C═O)—O—R1, where R1 as previously defined;
• or
• (g) —(C═O)—NH—R2, where R2 as previously defined;
• M is absent or selected from:
• (a) —O—;
• (b) —S—;
• (c) —NH—;
• or
• (d) —NR1—, wherein R1 is previously defined;
• Q is selected from:
• (a) aryl;
• (b) substituted aryl;
• (c) heteroaryl;
• (d) substituted heteroaryl;
• (e) heterocycloalkyl;
• or
• (f) substituted heterocycloalkyl;
• j=0, 1, 2, 3, or 4;
• n=0, 1, or 2;
• and
• s=0, 1, or 2.